Laparoscopic Versus Open Surgery for the Management of Cystic Echinococcosis of the Liver
NCT01643018 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 350
Last updated 2012-07-17
Summary
Echinococcosis in humans is a parasitic tapeworm infection, caused by a larval stage (the metacestode) of Echinococcus species. The infection can be asymptomatic or severe, causing extensive organ damage and even death of the patient.
Echinococcosis is one of the most neglected parasitic diseases and the lack of the prospective randomised studies supports this idea. Development of new drugs and other treatment modalities receives very little attention, if any. In most developed countries, Cystic Echinococcosis (CE) is an imported disease of very low incidence and prevalence and is found almost exclusively in migrants from endemic regions. In endemic regions, predominantly settings with limited resources, patient numbers are high.
The aim of the hydatid cyst treatment is the death of the parasite and consequently the cure of the disease. It has to be done with a minimal risk and maximum comfort for the patient, and always paying attention to avoid complications, secondary hydatidosis, and relapses.
There are several treatment modalities. Of them the most preferred surgical method is traditional cyst management through a laparotomy incision. Same can be done with laparoscopy. In the past 15 years significant advances in laparoscopic surgical skills and techniques combined with explosive advances in laparoscopic technology have encouraged the application of laparoscopy to the evaluation and treatment of solid organs including the liver. There are many studies about the laparoscopic treatment of liver hydatid cyst published in the literature and the feasibility of this procedure has been demonstrated by them. While the majority of them are case reports or case series, there are some relatively large series comparing open versus laparoscopic surgery published in the last decade, which all are not randomized trial.
Conditions
- Echinococcosis, Hepatic
- Hydatid Cyst
Interventions
- PROCEDURE
-
laparoscopic surgery
In laparoscopy group three trocars is used. The first is 10 mm and inserted within the umbilicus for telescop, the second is 10 mm and inserted just below the xiphoid process, and third is 5 mm and inserted at the right upper quadrant of the abdomen.
- PROCEDURE
-
open surgery
-open surgery group describes the patients treated with traditional open surgery. In open surgery group a right subcostal incision is used.
Sponsors & Collaborators
-
Medical Park Gaziantep Hospital
lead OTHER
Principal Investigators
-
MEHMET KAPLAN, MD · Medical Park Gaziantep Hospital, Gaziantep, Turkey
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-11-30
- Primary Completion
- 2010-11-30
- Completion
- 2012-05-31
Countries
- Turkey (Türkiye)
Study Locations
More Related Trials
-
Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis
NCT06478602 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Combining Pasireotide With Aspiration Sclerotherapy to Improve Volume Reduction of Hepatic Cysts
NCT02048319 ·Status: COMPLETED ·Phase: PHASE3
-
Stapler vs. LigaSure in Elective Hepatic Resection
NCT01858987 ·Status: COMPLETED ·Phase: NA
-
Sirolimus for Massive Polycystic Liver
NCT01680250 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®
NCT05900050 ·Status: TERMINATED ·Phase: PHASE2
-
Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis.
NCT02721264 ·Status: UNKNOWN ·Phase: NA
-
Fecal Microbiota Transplantation for Decompensated Cirrhosis
NCT03014505 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Faecal Microbiota Transplantation for Liver Cirrhosis
NCT04932577 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Fecal Microbiota Therapy Versus Standard Therapy in Decompensated NASH Related Cirrhosis: A Randomized Controlled Trial.
NCT02868164 ·Status: WITHDRAWN ·Phase: NA
-
Carvedilol, Endoscopic Variceal Ligation or Combination of Both for Prevention of First Variceal Bleed in Child's B & C Cirrhosis
NCT03069339 ·Status: UNKNOWN ·Phase: NA
-
Fecal Microbiome Transplantation in Cirrhosis: Trial in Patients With Decompensated Cirrhosis
NCT06533852 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Danazol for Treatment of Cytopenias in Patients With Cirrhosis
NCT04873102 ·Status: RECRUITING ·Phase: PHASE2
-
Umbilical Cord Mesenchymal Stem Cell Transplantation for Decompensated Hepatitis B Cirrhosis
NCT05106972 ·Status: RECRUITING ·Phase: NA
-
Autologous Mesenchymal Stem Cell Transplantation in Liver Cirrhosis
NCT01499459 ·Status: UNKNOWN ·Phase: NA
-
Deciphering the Mechanisms Involved in Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis
NCT02400216 ·Status: COMPLETED
-
Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis
NCT01766713 ·Status: COMPLETED ·Phase: PHASE2
-
Laparoscopic Partial Splenectomy for Hypersplenism in Liver Cirrhosis Patients
NCT07205471 ·Status: RECRUITING ·Phase: NA
-
A Comparison of Fecal Microbiota Transplantation and Steroid Therapy in Patients With Severe Alcoholic Hepatitis.
NCT03091010 ·Status: UNKNOWN ·Phase: NA
-
A Clinical Study to Evaluate the Safety and Efficacy of Mesenchymal Stem Cells in Liver Cirrhosis
NCT01877759 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Percutaneous Versus Endoscopic Ultrasound-guided Liver Biopsy (PEREUS)
NCT05295537 ·Status: COMPLETED ·Phase: NA
-
Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease
NCT02021110 ·Status: COMPLETED ·Phase: PHASE2
-
Long Term Follow up Mesenchymal Stem Cell Therapy for Patients Virus-related Liver Cirrhosis
NCT05080465 ·Status: COMPLETED ·Phase: PHASE3
-
G-CSF in Decompensated Cirrhosis: an Open Label Trial
NCT03415698 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Safety and Feasibility of Human Umbilical Cord Mesenchymal Stem Cell-Derived Secretome in the Treatment of Liver Cirrhosis: a Comprehensive Evaluation of Fibrosis Reduction, Immunomodulation, and Hepatic Regeneration: a Single Center, Randomized, Phase I Clinical Trial
NCT06629909 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Efficacy of Rifaximin on Hepatosteatosis and Steatohepatitis Patients
NCT02009592 ·Status: COMPLETED ·Phase: NA